药明康德“回马枪”:5亿元增资药明生基,CGT CDMO赛道激战愈酣

21世纪经济报道
19 Feb

国家企业信用信息公示系统显示,日前,上海药明生基发生工商信息变更,投资人由无锡生基变更为药明康德,注册资本也由1亿元变更为6亿元,增幅达500%。目前,上海药明生基的法定代表人为张朝晖,其同时也是药明康德的实控人之一。图片来源:国家企业信用信息公示系统  公开资料显示,无锡生基是药明康德在2017年成立的全资子公司,也是药明康德在CGT(细胞与基因治疗)领域的业务载体。近段时间,药明康德在CGT...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10